Arcellx Stock Dips on Kelonia's Early CAR-T Data: Analyst Calls Reaction "Overdone"

Guggenheim analyst says Arcellx stock decline is overdone after competitor Kelonia released early Phase 1 CAR-T therapy data. Maintains Buy rating despite market pressure.